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Chronic migraine afflicts 1-5% of the global population
and poses a substantial burden on subjects’ quality of life
and on health services utilization [1]. Although most
patients benefit from abortive and preventive drugs, a
subgroup of patients remains refractory to treatment.
Refractory chronic migraine is one of the greatest chal-
lenges in headache medicine and, in these patients, inva-
sive techniques should be considered.
In the past 20 years neuromodulatory approaches,
already proved effective in other chronic pain syndromes,
have been increasingly used for refractory primary
headaches.
Neuromodulation, a reversible and adjustable manipula-
tion of pain pathways is an evidence-based invasive treat-
ment for chronic pain conditions and it may be applied to
any neural structure: spinal cord, deep brain, and periph-
eral nerves.
Recently, three 12-week follow-up prospective, rando-
mised trials have been conducted to validate occipital
nerve stimulation in chronic migraine and intractable
chronic migraine associated to occipital localization of
pain. Considering the primary outcomes (50% reduction
in pain intensity, 50% decrease of headache days) all the
three trials have failed. In one of these studies [2],
although the second follow-up at 52 weeks has shown
important effects on pain severity, headache days, HIT-6
and MIDAS scores (60% of patients achieved 30%
reduction in headache days and/or pain, 50% achieved
50% reduction in headache days and/or pain, 70%
reported excellent or good headache relief and improved
QoL, 70% would undergo the procedure again), it has
also shown high incidence of adverse events related to
the procedure (70% of patients experienced at least one
AE, 41% of AEs required supplemental surgery, 8.6% of
AEs required hospitalization).
A more recent prospective, open-label, exploratory study
[3] assessing the long-term (6-months) safety, tolerability
and efficacy of cervical high frequency (10 kHz), paresthe-
sia-free, spinal cord stimulation in a cohort of 14 refrac-
tory chronic migraine patients (refractory also to
Onabotulinumtoxin-A) has shown good results on reduc-
tion of headache days, medication intake, HIT-6 and
MIDAS scores. The patients were carefully selected, for
refractory chronic migraine, not considering topographic
criteria for localization of pain, and were assessed by two
different psychologists before eligibility. A significant
reduction in headache days was observed at 24 weeks
(average 7.0 days). Seven (50%) subjects recorded a >30%
decrease in headache days, while 5 (36%) subjects reported
a reduction in headache days greater than 50%. Eight sub-
jects (57%) reverted to an episodic pattern of headache
(<15 days a month). Medication intake reduced signifi-
cantly, and four subjects discontinued triptans. Few
adverse events have been reported.
HF10-SCS deserves further clinical investigations to
evaluate its possible role in the management of rCM.
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